Monday, May 06, 2019
You can also take help of herbal order levitra http://cute-n-tiny.com/cute-animals/big-fat-cat/ pills that can help you to treat this condition. First of all, 100mg tablets of viagra cute-n-tiny.com this particular medication works similarly to the erectile dysfunction. There have been cases of viagra uk damaging penile tissues and this led to impotence. Testosterone buying this india generic cialis also plays a key role in keeping the intimacy alive and two partners bonded to each other.
Pluristem Therapeutics Inc. , a leading regenerative medicine company developing novel placenta-based cell therapy products, announced that it has filed a U.S. provisional patent application titled “Methods and Compositions for Producing Cannabinoids,” which covers the use of Pluristem’s state-of-the-art, proprietary 3-D cell culturing technology for the potential manufacturing of cannabinoid-producing cells.
The potential of successful adaptation to the industrial production of cannabinoid is to shift the cannabis industry from agriculture-based growing, which consists of resource-intensive and low-yield processes, into a full Good Manufacturing Practice (GMP) 3-D cell culturing platform for growing and expanding cannabinoid-producing cells in an automated and controlled manner at potentially significantly higher scales with the batch-to-batch consistency of commercial-grade products.
“We believe that Pluristem’s key competitive advantage is its advanced manufacturing platform that we developed in order to secure our leading position in the cell therapy industry with several product candidates in phase III studies,” said Pluristem President and Co-CEO, Yaky Yanay. “Any future development with respect to cannabinoid producing cells is expected to include third party funding of development expenses. Further, in exploring such development, Pluristem intends to comply with applicable regulations and Nasdaq standards.”
“We believe that the cannabis industry could be a very attractive opportunity to further leverage our advanced technology and manufacturing capabilities, while maintaining our competitive advantage in the cellular therapy field,” added Mr. Yanay. “Pluristem’s management team is focused on the advancement of our PLX cell therapy products and is making the necessary preparations for entering the marketing phase. In parallel, we look forward to further exploring the potential contribution our technology has on developing next-generation cannabinoid production while also potentially creating significant value for Pluristem’s shareholders.”
Source: Company Press Release